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INTRODUCTION
Every individual is characterized by a specific “enterotype,” based on the major components
of her/his microbiome (i.e., collection of host and microorganism genomes and environmental
conditions in an ecosystem) of the gut influenced by diet and geography. This is also influenced by
the effects of the organisms present in the infancy as well as the type and pattern of the individual
immune system (1).
In the last few years, a close biological relationship has emerged among the microbiome of the
gut, the metabolism of the body, as well as the immune system including cancer development. With
the increasing availability of high-throughput sequencing, single-cell transcriptomics, and mass
spectrometry for a very precise characterization of single enteric, neoplastic, and immune cells, and
more extensive databases of organisms already sequenced, experimental exploration of this network
has become possible. These advances have also included “culturomics” to make an ever-expanding
portion of the microbiota investigable, and sophisticated bioinformatics implements in order to
achieve data deconvolution and combination. In 2008, the Human Microbiome Project (HMP)
started to characterize the microbial communities from 300 healthy individuals, providing one
of the broadest microbial genome databases targeting different body sites: nares, oral cavity, skin,
gastrointestinal tract, breast, and urogenital tract (2, 3) (Figure 1).
MICROBIOME AND CANCER
In 2017, many experimental studies had been published to demonstrate the importance of single
bacterial species on the intestine, the individual immune response and cancer progression, and
response to therapy. One of the first unexpected pieces of evidence was that secondary tumor
deposits in patients with colorectal cancers include bacteria, such as Fusobacterium species,
including Bacteroides, Prevotella, and Selenomonas species, and its associated microbiome. These
findings demonstrated the microbiome stability between paired primary and metastatic tumors.
Antibiotic treatment of Fusobacterium-positive colon cancers mice-xenografts reduces tumor
growth, cancer cell proliferation along with Fusobacterium load, which favors the hypothesis that
Fusobacterium species is associated with neoplastic progression (5, 6).
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FIGURE 1 | Typical major phyla and genera of the human gut microbiome
[reproduced with permission from Goodman and Gardner (4)].
In breast cancer, bacterium Methylobacterium radiotolerans
was found relatively enriched compared to normal adjacent
tissue from the same patient. Furthermore, bacterial DNA
load was reduced in cancer samples vs. healthy tissue and
correlated inversely with advanced disease (7, 8). In the distal
esophagus, the impact of the microbiome in the pathogenesis
of reflux-related disorders and in the development of intestinal
metaplasia is well-demonstrated. Patients with esophagitis and
Barrett’s esophagus have a greater proportion of gram-negative
anaerobes/microaerophiles with respect the normal controls.
This altered microbiome may promote Barrett’s metaplasia and
progression to adenocarcinoma (9, 10). The compositions of
bacteria community and the throat biodiversity in laryngeal
carcinoma patients compared to a control population were
different and might be a risk factor for laryngeal carcinoma (11).
The most clinical-affecting evidence regarding cancer
microbiome is its contribution to therapy resistance. In
pancreatic cancer the most common species identified
belong to the Enterobacteriaceae and Pseudomonadaceae
families. Enterobacteriaceae express a bacterial enzyme cytidine
deaminase (CDD) isoform that confer resistance to gemcitabine.
Supporting this, co-treatment with the antibiotic ciprofloxacin
abrogate the gemcitabine resistance in colon cancer mouse
models (12).
On the other side, there is evidence that corroborates the
hypothesis of a protection role of microbiome toward neoplastic
changes. Hence, results show that individuals with microbiota
linked to a plant diet are the ones with a lower incidence of cancer
of the colon (13). Such a diet stimulates bacteria to produce short-
chain fatty acids (SCFAs), particularly butyrate, propionate, and
acetate. These fatty acids show an anti-inflammatory property
through the induction of T-regulatory cells of colonic tissues.
Connections of microbiome, production of short-chain fatty
acids, and the immune system become more interesting when
researchers started to explore the influence of the microbiome in
relation to immunotherapy drugs response.
MICROBIOME AND IMMUNOTHERAPY
DRUGS RESPONSE
Immunotherapy based on and programmed death-ligand 1 (PD-
L1)- and programmed death 1 (PD-1)-targeted antibodies has
profoundly modified the prognostic and therapeutic landscape
for many types of tumors, with demonstrated efficacy against
renal cell carcinoma (RCC), non–small cell lung cancer (NSCLC),
and melanoma. PD-L1 tissue expression is a poor prognostic
factor as well as a predictor of good responses from both
PD-1 and PD-L1 inhibitors in urothelial carcinoma (UC) and
RCC (14). In a recent meta-analysis on the expression of PD-
1 and PD-L1 in solid tumors, as a predictive biomarker of
benefit from PD-1/PD-L1 axis inhibitors, odds ratios of objective
response in PD-L1–positive patients compared with PD-L1–
negative patients was 2.34 for RCC and 2.20 for bladder cancer
(15). Liu et al. also confirmed that “patients with higher ratios of
PD-L1-positive cells responded significantly better to both PD-
1 and PD-L1 antibodies than those with lower ratios of PD-L1-
positive cells” (16).
Each PD-1/PD-L1 drug approved by FDA is associated with a
PD-L1, a immunohistochemistry (IHC)-based tissue assay. IHC-
based PD-L1 assay is basically utilized to potentially predict the
response to anti-PD-1 or/and anti-PD-L1 therapies. A fraction
of patients with a negative IHC assay can show a response. This
means that identification and utilization of other biomarkers is
of great importance for a better selection of patients who might
respond to such therapies.
Primary resistance to Immune checkpoint inhibitors (ICIs)
has been linked to different factors, including poor intrinsic
antigenicity of malignant cells, lack of priming by potentially
immunogenic pretreatment with radio-, or/and chemotherapy
(17), poor antigen presentation at the time of the priming
phase (18), immunosuppression exerted locally by extracellular
metabolites (19), and functional exhaustion of lymphocytes
infiltrating the tumor (20, 21). On the contrary, high mutational
burden and high immunogenic antigenicity of malignant cells are
in favor of a better response to ICIs (22, 23). Recently, Routy
et al. demonstrated that abnormal gut microbiome composition
could have an influence on primary resistance to PD-1blockade
in mice xenografts and patients with cancer. In particular,
they showed that the clinical benefit of ICIs in patients with
cancer at an advanced stage is inhibited by antibiotic therapy
(ATB) (24). They tested the effect of ATB on patients with
advanced UC, RCC, or NSCLC, who had received PD-1/PD-
L1mAb following one or several previous therapies. Progression-
free survival (PFS) and overall survival (OS) were significantly
shorter in the ATB-treated cohort when either all patients
were combined together or when individual cancer types were
investigated. In univariate and multivariate analyses, ATB was a
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FIGURE 2 | Proposed model on the role of microbiota in resuming the response to immune checkpoint inhibitors [reproduced with permission from Santoni et al. (28)].
predictor factor for resistance to PD-1 blockade, not dependent
from traditional prognostic markers in RCC and NSCLC. To
evaluate the composition of the microbiota of the gut, they used
quantitativemetagenomics with analysis of the data in a reference
catalog of 9.9 million genes. The greatest richness of the samples,
analyzed at the levels of metagenomic species (MGS) and gene
count, was correlated with the clinical response. This was defined
by the lack of progression of disease 6 months following the
initiation of ICIs.
Akkermansia muciniphila (A. muciniphila) was the
commensal associated most significantly with excellent clinical
outcomes in both RCC and NSCLC. When analyzing memory
T cell responses from the peripheral blood of the patients,
stimulated against microbiota following initiation of PD-1
blockade, the only immune response linked with the clinical
benefit at the time of immunotherapy was the Th1 and Tc1
cell reactivity against A. muciniphila. This immunomodulatory
effect might be explained by the production of SCFAs, such as
propionate and acetate, by A. muciniphila. These short-chain
fatty acids are ligands of the two orphan G-protein–coupled
receptors 41 and 43 (GPR41 and GPR43). The former regulates
the tumor cells apoptosis induced by SCFA and so exerts a tumor
suppressor activity. Furthermore, propionate produced by the
bacterium inhibits histone deacetylases and thus increases the
histone hyperacetylation.
The inhibition of the expression of Histone Deacetylases
(HDACs) has several effects, ranging from a pro-apoptotic
activity to a pro-inflammatory response. By opening cell
chromatin and thus increasing the DNA accessibility to
transcription factors, the histone hyperacetylation induces
overexpression of caspases 6, 7, and 8, including caspase 3,
and reduces the inhibitor of apoptosis (IAP) family expression
(25). The inhibition of expression the HDACs activates the
mTOR-S6K and STAT3 pathways. All this stimulates Th17, Th1,
FoxP3+, and IL-10+ T cells, as well as the production of
IL-10, IFN-g, and IL-17 in CD8+ T cells in both Tc1- and
Tc17-cell subsets (26). Moreover, propionate promotes T-cell
migration by increasing the expression of intercellular adhesion
molecule 1 (ICAM-1) and E-selectin on endothelial cells
(27, 28) (Figure 2).
Derosa et al. demonstrated the effect of ATB in patients with
RCC and NSCLC treated with anti-PDL1 mAb monotherapy or
combination therapy. In patients with RCC, ATB compared with
no ATB was linked with an increased risk of progressive disease,
shorter PFS, and shorter OS. Similar rates were also obtained
in the NSCLC cohort (29). Researchers are now planning to
transfer fecal bacteria from patients who respond to treatment
with checkpoint inhibitors into the intestine of non-responder
patients. This process is currently called “fecal microbiome
transplant.” Microbiota composition might also be manipulated
by the application of foods and prebiotics. The prevalence of a
subspecies selected by diet rather than others could modify the
population predisposition to a specific disease and the response
to therapy of cancer patients (30). Fecal microbiota transplant,
although not being probiotic, could be considered a fermented
food, given the microbes, and nutrients present.
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TABLE 1 | Metagenomic human studies identifying microbiota associated with
cancer tissues [reproduced with permission from Goodman and Gardner (4)].
Tissue type Species differential References
Colorectal cancer Fusobacterium,
Selenomonas, and
Leptotrichia species
increased in cancer tissues
(5, 6)
Breast cancer Alistipes, Sphingomonas,
and Methylbacterium
increased in cancer tissue
(7, 8)
Esophageal
cancer
Streptococcus, Prevotella,
and Veillonella species
increased in cancer tissues
(9, 10)
Head and neck
cancer
Fusobacterium, Prevotella,
and Gemella species
increased in cancer tissues;
Streptococcus and Rothia
species decreased in
cancer tissues
(11)
Pancreatic cancer Enterobacteriaceae,
Pseudomonadaceae,
Moraxellaceae, and
Enterococcaceae increased
in cancer tissues
(12)
Prostate cancer Propionobacterium acnes
increased in cancer tissues
(32–37)
MICROBIOME IN BLADDER AND
PROSTATE CANCER
Of great interest is the urinary microbiota profile investigated
by Wu et al. They analyzed DNA from urine pellet collected
from male patients with urothelial carcinoma and non-
neoplastic controls. They observed enrichment of some
bacterial genera (such as Sphingobacterium, Anaerococcus,
and Acinetobacter) and decrease of others (such as
Roseomonas, Proteus, and Serratia) in the group with cancer
in comparison with the control group. Patients with high
risk of recurrence and progression had an enrichment of
Herbaspirillum, Porphyrobacter, and Bacteroides. This means
these bacteria can be considered as potential biomarkers in risk
stratification (31).
In the last year, interesting results have emerged by
investigations on the microbiome in PCa patients. The
microflora of tumor, peri-tumor, and benign prostate
tissue samples have recently been characterized by massive
ultradeep pyrosequencing. Interestingly, differences in microbial
populations among paired tumor/peri-tumor and non-tumor
prostate tissues have been detected. This finding generates
the hypothesis that the distribution of bacterial microbes
varies according to the nature of tissue within the same gland.
This suggests a pathophysiological association between the
local microbial niche and composition, and the tumor itself
(32, 33) (Table 1).
A case-control pilot study has been conducted by Golombos
et al. to demonstrate the impact of the gut microbiota on
PCa pathogenesis. They performed a computational genomics
analysis on stool samples of men with benign prostatic conditions
and men with intermediate or high risk clinically localized
PCa. Biologically significant abundance differences of bacteria
species and 23 metabolic differentially abundant pathways were
identified between the two cohorts (34). Likewise, analyses on
the urinary microbiome showed a prevalence of uropathogens
and pro-inflammatory bacteria differentially abundant in PCa
patients compared to healthy subjects in urine collected from
men prior to biopsy for PCa (35).
Liss et al. developed a microbiome-derived risk profile for
PCa, derived from altered metabolic pathways, comparing the
taxonomic composition of samples (64 with PCa and 41 without)
of rectal swab collected 2 weeks before prostate biopsy (36).
Even though the differences between the two groups are not
impressive, these results are hypothesis-generating and pave
the way to further evaluate the manipulation of aberrant
microbiomes to reduce PCa risk (3).
The composition of the microbiota in the gut is influenced
by oral androgen receptor axis-targeted therapies (ATT) in
prostate cancer patients. Results on fecal microbiota profile
shows the abundance of species linked to response to anti-
PD-1 immunotherapy, including Ruminococcaceae spp., and
A. muciniphila, and an greater representation of bacterial gene
pathways that are involved in steroid biosynthesis as well as
steroid hormone biosynthesis in the fecal microbiota of men
under ATT (4, 37). Additional studies are needed to evaluate
whether the gut microbiota can influence clinical responses to
ATT, and modulate the anticancer effects of future therapies,
including immunotherapy.
As regards to genitourinary tumors, there are only few trials
ongoing (38, 39). One to take into consideration is a prospective
study on prostate cancer and breast cancer patients who are
undergoing two different standards of care radiation regimens.
Exposure to radiation can impact immune cells that are present
in the blood as well as the underlying microbiota. The aim of
this study is to study microbial changes and how these changes
correlate with alteration in immune mediators (i.e., lymphocytes,
cytokines) present in blood samples before, during, and after
radiation, by collecting stool specimens at baseline, end of
radiation therapy and during the follow up (ClinicalTrials.gov
Identifier: NCT03383107).
CONCLUSIONS
The host and the microbiota share a complex balanced
relationship that can be overthrown in a state of dysbiosis
consequential to environmental changes. Alteration of this
balance could lead to promotion of inflammatory diseases
and cancer. There is evidence showing that the activity
of microbiota in the restoration of response to immune
checkpoint inhibitors involves both the immune and cancer
cells. Stimulating recall Th1 responses against A. muciniphila
improves immunosurveillance in cancer patients. Microbiome
composition has the potential to be a novel biomarker of response
to ICIs and a therapeutic opportunity for unresponsive patients.
In patients with RCC, antibiotic therapy was linked to an
increased risk of progressive disease, shorter PFS, and shorter
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OS. Pioneer studies on bladder and prostate cancer patients’
microbiome pave the way to the investigation of a possible novel
prognostic, diagnostic, and therapeutic tool.
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